What is the recommended treatment for giant cell arteritis?

Giant Cell Arteritis Treatment

Immediate Initial Management

Start high-dose oral glucocorticoids (prednisone 40-60 mg daily or 1 mg/kg/day) immediately upon clinical suspicion of GCA without waiting for diagnostic confirmation, and strongly consider adding tocilizumab 162 mg subcutaneously weekly from the outset to reduce glucocorticoid exposure and prevent relapse. 1, 2, 3

Standard Presentation (No Vision Threat)

• Initiate prednisone 40-60 mg daily as a single morning dose 1, 2
• Daily dosing is superior to alternate-day schedules for achieving remission 1, 3
• High-dose oral glucocorticoids are preferred over IV pulse steroids for patients without cranial ischemic symptoms 1

Vision-Threatening Presentation

• Administer IV methylprednisolone 500-1000 mg daily for 3 consecutive days before transitioning to oral therapy for patients with threatened vision loss, amaurosis fugax, or acute visual symptoms 1, 2
• This approach is critical as visual loss occurs in 15-35% of patients, primarily before treatment initiation, and the risk of losing vision in the second eye approaches 50% without prompt treatment 3

Glucocorticoid-Sparing Therapy

Add tocilizumab 162 mg subcutaneously weekly (or 8 mg/kg IV every 4 weeks) at diagnosis for all newly diagnosed patients to achieve superior glucocorticoid-sparing effects and reduce relapse rates. 1, 2, 3

• Tocilizumab is FDA-approved specifically for GCA and demonstrates high-quality evidence (low to high certainty) for reducing relapse and cumulative steroid exposure 1, 3
• Weekly tocilizumab with a 26-week GC taper achieved remission rates 4 times higher than 52-week GC taper alone (risk ratio 4.00,95% CI 1.97-8.12) 4
• If tocilizumab is unavailable or contraindicated, consider methotrexate 15-25 mg weekly as an alternative steroid-sparing agent, though it is less effective 2, 5

Adjunctive Cardiovascular Protection

• Prescribe low-dose aspirin 75-150 mg daily to all GCA patients to reduce cardiovascular and cerebrovascular ischemic events 2, 3
• For patients with critical or flow-limiting involvement of vertebral or carotid arteries, adding aspirin is particularly important 1, 3

Glucocorticoid Tapering Protocol

• Maintain initial high dose (40-60 mg daily) for one month if disease is controlled 2, 3
• Begin gradual taper guided by clinical symptoms and inflammatory markers (ESR/CRP) after the first month 2, 3
• Target dose of 10-15 mg daily at 3 months 2, 3
• Aim for ≤5 mg daily at 12 months if disease remains controlled 2, 3
• The optimal duration of GC therapy is not well established and should be guided by individual response, but many patients require treatment for several years 1, 5

Special Clinical Scenarios

Extracranial Large Vessel GCA

• Combine oral glucocorticoids with a non-glucocorticoid immunosuppressive agent (preferably tocilizumab) from the outset 1, 3
• Obtain baseline noninvasive vascular imaging (MR or CT angiography of neck/chest/abdomen/pelvis) at diagnosis to evaluate large vessel involvement 1, 2, 3

Disease Relapse Management

• For relapse while receiving moderate-to-high dose glucocorticoids: add a non-glucocorticoid immunosuppressive agent rather than simply increasing glucocorticoid dose 1, 3
• For relapse with symptoms of cranial ischemia: add tocilizumab (preferred over methotrexate) AND increase glucocorticoid dose to prevent irreversible complications 1, 3
• Up to 60% of patients experience one or more relapses during glucocorticoid tapering, making adjunctive therapy particularly important 3

Monitoring and Surveillance

• Measure ESR and CRP at each visit to guide treatment decisions and tapering 2, 3
• All patients in apparent remission require long-term clinical monitoring to detect relapses early 1, 3
• Isolated elevation of inflammatory markers without clinical symptoms warrants observation and monitoring without immediate treatment escalation 1, 3
• Repeat vascular imaging may be considered to assess disease progression, though optimal timing is not well established 2, 3

Glucocorticoid Toxicity Prevention

• Initiate bone protection therapy (calcium, vitamin D, bisphosphonates) for all patients unless contraindicated, as GC-related toxicity occurs in up to 85% of patients 1, 2, 3
• Monitor blood pressure closely during high-dose glucocorticoid therapy, particularly in patients with pre-existing hypertension or cardiovascular disease 6
• Screen for and manage other glucocorticoid-related complications including hyperglycemia, infections, and psychiatric symptoms 1, 3

Treatment Target

• The primary treatment target is achievement and maintenance of remission, defined as absence of clinical symptoms and systemic inflammation 1, 3
• Prevention of tissue ischemia and vascular damage are equally important goals 1, 3
• Treatment decisions should be based on shared decision-making between patient and physician, recognizing the need for urgent treatment to avoid ischemic complications while maximizing health-related quality of life 1

Common Pitfalls to Avoid

• Do not delay treatment while awaiting temporal artery biopsy, as biopsy can be performed within 2 weeks of starting glucocorticoids without significantly affecting diagnostic yield 1
• Do not use statins specifically for the treatment of GCA, as evidence does not support their efficacy for this indication 1
• Do not rely solely on inflammatory markers for treatment decisions during relapse, as clinical symptoms are paramount 1, 3
• Do not use moderate-dose glucocorticoids (30-40 mg daily) as initial therapy except in highly selected patients with significant risk of severe glucocorticoid toxicity and low risk of vision loss 2